2.4 Existing Problems in the Blood Coagulation Industry and Influencing Factors
2.4.1 Implementation of in Vitro Diagnosis of Thrombosis and Hemostasis in the Chinese Market
After 2000, more and more hospitals are equipped with the blood coagulation analyzers, and carry out testing of four screening items (PT/APTT/FIB/TT) in the clinical laboratory, which are mainly used for screening and diagnosis of clinical bleeding risk, etc. to dramatically reduce the occurrence of intraoperative bleeding and postoperative complications. This brings the first round of rapid development of the in vitro diagnostic market for thrombosis and hemostasis in China.
After 2007, with the improvement of clinical academic awareness of thrombotic diseases, some test items of fibrinolysis and anticoagulation (D-D/FDP/AT) are gradually carried in Grade III hospitals; after 2012, these test items were gradually popularized in Grade II and below hospitals. The above diagnostic items can help doctors to control the risk of thrombosis in the diagnosis and treatment, reduce the risk of thrombosis in the post-operative populations, pregnant women, and patients with cardiovascular and cerebrovascular diseases, and promote the second development of the IVD market for thrombosis and hemostasis. After 2015, Grade III Level A hospitals began to carry out more testing projects, such as monitoring of new oral anticoagulants, diagnosis of thrombophilia, and diagnosis of antiphospholipid syndrome, etc., together with the development trend of clinical targeted monitoring and precision treatment, the level of individualized diagnosis and treatment is enhanced, allowing doctors to accurately formulate diagnosis and treatment protocol for thrombosis and hemorrhage and promoting the development of the diagnosis of thrombosis and hemostasis. Since China has the largest population, with the development of the aging process, there will be an increasing number of patients with thrombotic diseases year by year. In the future, with the development of research and technologies, thrombosis and hemostasis diagnosis will develop dramatically in the Chinese market.
Last: In Vitro Diagnostic Industry in China - Diagnosis of Blood and Body Fluids X
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.